MHE Staff

Articles by MHE Staff

Developer of EndeavorRx, a game-based treatment for ADHD, is pulling back from the pipeline and focusing on near-term growth, the CEO said in an email to employees.

Biosimilars started to gain a firm foothold in the market this year and could take off in 2023 with the advent of Humira biosimilars. Our articles about biosimilars were some of the most viewed of the year.

Pharmacy benefit managers (PBMs) were in the news in 2022, and Managed Healthcare Executive®’s coverage of PBMs garnered a great deal of attention.

Amendola Communications collected 10 predictions for developments in healthcare in 2023 from leaders in the field.

In this Managed Healthcare Executive® K-Cast, David Rosmarin, M.D., vice chair of education and research in the Department of Dermatology at Tufts Medical Center in Boston, discussed the economic burden, treatment goals, treatment options and health insurance issues related to vitiligo.